Moscow State University has initiated clinical trials for “Mederig,” a revolutionary drug aimed at treating severe male infertility, including conditions such as azoospermia, where sperm is absent. The Russian News Agency “TASS” reported that the trials have been approved by Russia’s Ministry of Health and are set to evaluate the drug’s effectiveness in treating infertility in men.
“Mederig,” which is derived from human mesenchymal stromal cells, represents a novel treatment option for men who previously had limited or no alternatives. The ongoing clinical trials will be conducted in two phases, targeting men aged between 21 and 60.
Preliminary animal studies have shown encouraging results, with infertile male mice regaining fertility and successfully producing healthy offspring after treatment with the drug.
The research is being led by Moscow State University’s teams specializing in medical science and regenerative medicine. Over 126 million rubles have been allocated for the development and trial phases, in line with directives from the Russian government.
The scientific community is hopeful that “Mederig” could offer new treatment avenues for male infertility cases that have not responded to conventional therapies, bringing new possibilities for couples trying to conceive.
Related topics:
